Introduction
============

Cancer remains the leading cause of death worldwide, with approximately 14.1 million new cancer cases and 8.2 million deaths occurring in 2012 according to the GLOBOCAN estimates [@B1]. It has been estimated that about one-third of cancers are attributable to diet and lifestyle [@B2], and a number of studies have reported a relationship between folate intake and cancer risk [@B3]-[@B5].

Folate plays an important role in one-carbon metabolism, and acts as a coenzyme in DNA methylation and synthesis [@B6]. Folate can provide the methyl group donor S-adenosylmethionine for many biological reactions. It also plays a critical role in the de novo synthesis of purines and thymidylate, which are necessary for DNA replication and repair [@B7]. Abnormal folate metabolism can lead to the aberrant distribution of methyl groups and affect DNA biosynthesis and methylation, which is considered as a mechanism in the development of cancer [@B8].

Methionine synthase reductase (MTRR) is one of the key regulatory enzymes involved in the folate metabolic pathway. It can catalyze the regeneration of methyl cobalamin, which is a cofactor of methionine synthase (MTR) in the remethylation of homocysteine to methionine [@B9]. Because MTRR plays a vital role in maintaining the active state of MTR, genetic variation within the *MTRR* gene may be associated with cancer susceptibility. The *MTRR* gene is located on chromosome 5 at 5p15.2-p15.3, and the most common polymorphism is the substitution of isoleucine with methionine at position 22 (A66G; rs1801394). It has been suggested that the 66GG genotype is negatively correlated with plasma homocysteine levels [@B10]. A large number of studies have investigated the role of the *MTRR* A66G polymorphism and cancer risk [@B11]-[@B82], but the results remain controversial. Therefore, we conducted this updated meta-analysis from all eligible studies to derive a more precise estimation of this association.

Materials and methods
=====================

Search strategy
---------------

A comprehensive literature search was carried out in PubMed, Embase, and Chinese Biomedical (CBM) databases for all relevant articles using the following search terms: "*MTRR* or methionine synthase reductase or one-carbon metabolism", "polymorphism or variant or variation" and "cancer or tumor or carcinoma or neoplasm" (the last search was updated on October 21, 2016). Review articles and references cited in the searched studies were examined manually to identify additional relevant articles. Only the most recent study or the one with most participants was included in the final meta-analysis if two or more studies overlapped.

Inclusion and exclusion criteria
--------------------------------

The included studies met the following criteria: (1) case-control study design; (2) investigating the association between the *MTRR* A66G polymorphism and cancer risk; (3) providing detail information for calculating pooled odds ratios (ORs) and their 95% confidence intervals (CIs). Studies were excluded if one of the following existed: (1) not a case-control study; (2) duplicate publications; (3) without detail genotype frequencies; and (4) genotype frequencies in the controls departed from Hardy-Weinberg equilibrium (HWE).

Data extraction
---------------

Information was extracted from all eligible studies independently by two authors (Ping Wang and Meilin Wang) according to the inclusion and exclusion criteria listed above. Disagreement was resolved by discussion until consensus was reached. The following information was collected from each study: first author\'s surname, year of publication, country of origin, ethnicity, cancer type, control source (hospital-based or population-based), genotyping methods, and numbers of cases and controls with the AA, AG and GG genotypes. Ethnicities were categorized as Asians, Caucasians, Africans or Mixed, which included individuals belonging to more than one ethnic group.

Quality assessment
------------------

Quality assessment was performed by two authors independently according to the criteria as described previously [@B83]. Quality scores of studies ranged from 0 (lowest) to 15 (highest), and the studies were categorized into high quality (scores \> 9) and low quality (scores ≤ 9).

Statistical analysis
--------------------

The strength of association between the *MTRR* A66G polymorphism and cancer risk was assessed by calculating the ORs with the corresponding 95% CIs. The pooled ORs of 5 comparison models were calculated: homozygous model (GG *vs.*AA), heterozygous model (AG *vs.*AA), recessive model \[GG *vs.* (AA + AG)\], dominant model \[(GG +AG) *vs.*AA\] as well as an allele comparison (G *vs.*A). The Chi square-based Q-test was used to check heterogeneity between studies. A *P*value greater than 0.1 for the Q-test indicated the homogeneity among studies, in which case the fixed-effects model (the Mantel-Haenszel method) [@B84] was adopted. Otherwise, the random-effects model (the DerSimonian and Laird method) [@B85] was applied. Data were stratified by cancer type (if one cancer type was represented by fewer than two studies, it was merged into the "other cancers" group), ethnicity (Asians, Caucasians, Africans or Mixed), source of control (hospital-based studies and population-based studies), and quality scores (≤ 9 and \> 9). Potential publication bias was estimated using Begg\'s funnel plot [@B86] and Egger\'s linear regression test [@B87]. Sensitivity analysis was carried out to evaluate the effect of each individual study on the pooled ORs by excluding studies one-by-one and recalculating the ORs and 95% CIs.

For significant results found in the present meta-analysis, the false-positive report probability (FPRP) was used to evaluate positive associations. We calculated FPRP with 0.2 as a threshold and assigned a prior probability of 0.1 to detect an OR of 0.67/1.50 (protective/risk effects) for an association with genotypes under investigation. FPRP values \< 0.2 were considered as noteworthy associations [@B88]. All the statistical tests were performed with STATA version 12.0 (Stata Corporation, College Station, TX). All the *P* values were two-sided, and *P*\< 0.05 was considered statistically significant.

Results
=======

Study characteristics
---------------------

As shown in **Figure [1](#F1){ref-type="fig"}**, a total of 381 published records were identified from PubMed, Embase and CBM by using the search terms described above. By checking the reference lists, we identified 29 additional publications. After screening the abstracts and texts, only 96 publications met the crude inclusion criteria and were selected for further assessment. Among them, five were excluded for containing survival data only [@B89]-[@B93], seven lacked detailed data for further analysis [@B94]-[@B100], eleven deviated from HWE [@B101]-[@B111] and one was a case-only study [@B112]. Ultimately, 72 publications [@B11]-[@B82] were included in the final meta-analysis (**Table [1](#T1){ref-type="table"}**).

Of the 72 publications, two publications [@B11], [@B37] with different ethnic groups were separated as five independent studies and eight publications [@B12], [@B13], [@B29]-[@B31], [@B42], [@B44], [@B74] with different cancer types were also treated as 18 independent studies. For those studies [@B12], [@B13], [@B21], [@B25], [@B26], [@B29], [@B30], [@B32], [@B38], [@B39], [@B42], [@B50], [@B54], [@B63], [@B70], [@B74] with the same control group, the control numbers were calculated once in the total number. Overall, 72 publications including 85 studies of 32,272 cases and 37,427 controls were included in the final meta-analysis. Of the 85 studies, 20 studies focused on colorectal cancer [@B11], [@B14], [@B17], [@B18], [@B20], [@B31], [@B37], [@B40], [@B44], [@B49]-[@B52], [@B55], [@B66], [@B70], [@B71], ten on breast cancer [@B19], [@B22], [@B36], [@B38], [@B44], [@B47], [@B62], [@B64], [@B76], [@B82], nine on acute lymphoblastic leukemia (ALL) [@B13], [@B24], [@B29], [@B41], [@B42], [@B53], [@B56], [@B59], [@B60], eight on gastric cancer [@B12], [@B27], [@B31], [@B46], [@B65], [@B67], [@B74], [@B79], five on non-Hodgkin lymphoma (NHL) [@B13], [@B30], [@B32], [@B58], [@B78], four each on cervical cancer [@B48], [@B54], [@B68], [@B72] and liver cancer [@B33], [@B74], [@B75], [@B81], three each on prostate cancer [@B35], [@B45], [@B69], head and neck cancer [@B16], [@B25], [@B61] and brain cancer [@B28], [@B73], [@B77], and "other cancers" with no more than two studies. There were 37 studies on Asians, 32 studies on Caucasians, 13 studies on mixed ethnicities and three on Africans. Of all the studies, 52 were population-based and 33 were hospital-based. Furthermore, 37 studies were considered as low quality (quality score ≤ 9), and 48 studies (56.5%) were considered as high quality (quality score \> 9). Controls were matched for age, sex and ethnicity in most studies.

Meta-analysis results
---------------------

The main results of the meta-analysis are shown in **Table [2](#T2){ref-type="table"}** and **Figure [2](#F2){ref-type="fig"}**. Pooled analysis indicated a significant association between the *MTRR* A66G polymorphism and cancer risk (homozygous: OR = 1.08, 95% CI = 1.02-1.15, *P* = 0.009; recessive: OR = 1.06, 95% CI = 1.00-1.12, *P* \< 0.001 and allele comparison: OR = 1.03, 95% CI = 1.00-1.06,*P* \< 0.001). In the subgroup analysis, statistically significant associations were found for head and neck cancer (homozygous: OR = 1.49, 95% CI = 1.17-1.89, *P* = 0.768; dominant: OR = 1.30, 95% CI = 1.03-1.64, *P* = 0.143 and allele comparison: OR = 1.17, 95% CI = 1.04-1.31, *P* = 0.560), Caucasians (homozygous: OR = 1.09, 95% CI = 1.00-1.19, *P* = 0.077; dominant: OR = 1.08, 95% CI = 1.00-1.17, *P* = 0.045 and allele comparison: OR = 1.05, 95% CI = 1.01-1.09, *P* = 0.193), Africans (homozygous: OR = 1.52, 95% CI = 1.00-2.32, *P* = 0.577 and allele comparison: OR = 1.23, 95% CI = 1.01-1.49, *P* = 0.474) and high quality studies (homozygous: OR = 1.07, 95% CI = 1.00-1.15, *P* = 0.005 and recessive: OR = 1.06, 95% CI = 1.01-1.11,*P* = 0.262).

Heterogeneity and sensitivity analysis
--------------------------------------

Substantial heterogeneity was detected among all studies of the *MTRR* A66G polymorphism and overall cancer risk (homozygous: *P* = 0.009; heterozygous: *P* = 0.007; dominant: *P* = 0.001; recessive: *P* \< 0.001 and allele comparison: *P* \< 0.001). Therefore, the random-effects model was applied to generate wider CIs. Leave-one-out sensitivity analysis was performed and the results suggested the pooled ORs were not influenced by omitting any single study (data not shown).

Publication bias
----------------

As shown by the relative symmetric funnel plot (**Figure [3](#F3){ref-type="fig"}**) and Egger\'s test, no evidence of publication bias was found in the current analysis under any of the models (homozygous: *P* = 0.913; heterozygous: *P* = 0.551; dominant: *P* = 0.510; recessive: *P* = 0.666 and allele comparison: *P* = 0.560).

FPRP test results
-----------------

The significant associations were investigated using the FPRP test and the results were shown in **Table [3](#T3){ref-type="table"}**. For a prior probability of 0.1, the FPRP value was 0.128 for the *MTRR* A66G polymorphism with an increased cancer risk under the homozygous model, and positive associations were also found in head and neck cancer (homozygous: FPRP = 0.017 and allele comparison: FPRP = 0.055), Caucasians (allele comparison: FPRP = 0.087) and high score studies (recessive: FPRP = 0.106). However, no positive association was found between the *MTRR* A66G polymorphism and cancer risk in Africans.

Discussion
==========

Folate is a critical coenzyme in DNA synthesis, and the maintenance of methylation, and folate deficiency has been reported to be associated with various human malignancies [@B113], [@B114]. MTRR plays a key role in folate-dependent homocysteine remethylation and is required in the regulation of MTR activity. The A66G polymorphism is one of the most common polymorphisms in the *MTRR* gene, which was first reported in 1998 [@B115], and the variant enzyme has reduced affinity for MTR [@B116]. The reported associations between the *MTRR* A66G polymorphism and cancer susceptibility are inconsistent due to the small sample sizes in individual studies, ethnic differences and research methodology.

Our present study represents an updated comprehensive meta-analysis of the association between the *MTRR*A66G polymorphism and cancer risk and included 85 studies with 32,272 cases and 37,427 controls. The results revealed that the *MTRR* A66G polymorphism was significantly associated with an increased overall cancer risk. In the subgroup analysis, the association was more evident for head and neck cancer, Caucasians, Africans and high quality studies. However, the results for Africans need further validation due to the high probability of false-positive reports. Furthermore, no potential publication bias was detected by the funnel plot and Egger\'s regression test, indicating the robustness of the results in this study.

One previous meta-analysis focused on the *MTRR* A66G polymorphism and overall cancer risk. In the meta-analysis by Han *et al.*[@B117], which included 35 studies with 18,661 cases and 27,678 controls, an increased overall cancer risk was observed only under the allele comparison and homozygous model. In the subgroup analysis, significantly increased risks were found in Asians. We found this polymorphism to be associated with an increased overall risk also under the recessive model and increased cancer risks in head and neck cancer, Caucasians and Africans, but not in Asians, which were different from the previous meta-analysis; this result presumably occurred because our analysis was based on a much larger sample size, thereby increasing the statistical power. In the subgroup analysis by cancer type, we did not find any significant association between the *MTRR* A66G polymorphism and colorectal cancer in any comparison models, a finding that was inconsistent with previous meta-analyses [@B6], [@B118]. The discrepancy occurred because, in the current study, we added many recently published studies and even included several Chinese publications, allowing the more precise detection of an association.

Large and well-designed studies with "statistically significant" results for genetic variants turned out to be false-positive findings [@B119], [@B120]. Thus, we used the FPRP test to investigate positive associations in the current meta-analysis. Interestingly, the FPRP test results showed that the *MTRR* A66G polymorphism could actually increase cancer susceptibility. In the subgroup analysis, the FPRP test indicated that the *MTRR* A66G polymorphism increased cancer susceptibility in head and neck cancer, Caucasians and high score studies. The significant association with Africans in the present meta-analysis was false positive, which may due to the limited sample size.

Although we conducted a comprehensive literature search and included the latest studies on the *MTRR* A66G polymorphism and cancer risk, some possible limitations in this meta-analysis should be addressed. First, the number of cases in the individual studies was small (\<1000) in all but eight studies [@B15], [@B19], [@B22], [@B23], [@B28], [@B57], [@B65], [@B70]; this limitation may affect the investigation of the real association. Second, our results were based on unadjusted estimates, so the estimates were relatively imprecise. Third, the effects of gene-gene, and gene-environment interactions were not evaluated due to the lack of original data, which may affect cancer risk. Fourth, in the subgroup analysis, only three studies were carried out in Africans, which may lead to relatively weak power to detect the real association. Finally, only studies published in English and Chinese were included, so we may have missed publications in other languages.

In conclusion, we performed this updated meta-analysis with the latest published studies and obtained a more precise estimation of the association between the *MTRR* A66G polymorphism and cancer risk. However, it is necessary to conduct well-designed prospective studies with larger sample sizes to verify our findings.
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###### 

Characteristics of studies included in the meta-analysis.

  Surname \[ref\]              Year   Country        Ethnicity   Cancer type        Control   Genotype method       Case          Control       MAF           HWE           Score                        
  ---------------------------- ------ -------------- ----------- ------------------ --------- --------------------- ------------- ------------- ------------- ------------- ------- ----- ------ ------- ----
                                                                                    source                          AA            AG            GG            AA            AG      GG                   
  Le Marchand \[11\]           2002   USA            Asian       Colorectal         PB        PCR-RFLP              148           140           26            193           170     30    0.29   0.374   11
  Le Marchand \[11\]           2002   USA            Caucasian   Colorectal         PB        PCR-RFLP              26            81            40            45            86      39    0.48   0.865   10
  Le Marchand \[11\]           2002   USA            Mixed       Colorectal         PB        PCR-RFLP              30            34            12            40            38      9     0.32   0.995   9
  Stolzenberg-Solomon \[12\]   2003   China          Asian       Esophagus          PB        Real-time PCR         50            63            16            186           179     33    0.31   0.268   14
  Stolzenberg-Solomon \[12\]   2003   China          Asian       Gastric            PB        Real-time PCR         43            37            10            186           179     33    0.31   0.268   13
  Gemmati \[13\]               2004   Italy          Caucasian   ALL                PB        PCR-RFLP              28            58            23            59            122     76    0.47   0.457   10
  Gemmati \[13\]               2004   Italy          Caucasian   NHL                PB        PCR-RFLP              51            106           43            59            122     76    0.47   0.457   10
  Otani \[14\]                 2005   Japan          Asian       Colorectal         HB        Taqman                58            44            5             128           82      14    0.25   0.858   8
  Shi \[15\]                   2005   USA            Caucasian   Lung               HB        PCR-RFLP              162           503           370           231           542     375   0.44   0.168   11
  Zhang \[16\]                 2005   USA            Caucasian   Head and neck      HB        PCR-RFLP              114           376           231           276           589     369   0.46   0.161   11
  Chen \[17\] ^a^              2006   China          Asian       Colorectal         PB        PCR-RFLP              32            107 (AG+GG)   89            253 (AG+GG)   NA      NA    9              
  Koushik \[18\]               2006   USA            Mixed       Colorectal         PB        Taqman                82            159           116           163           399     245   0.45   0.981   14
  Shrubsole \[19\]             2006   China          Asian       Breast             PB        Taqman                621           393           70            687           422     76    0.24   0.304   14
  Hazra \[20\]                 2007   USA            Mixed       Colorectal         PB        Taqman                113           258           162           111           264     158   0.46   0.970   14
  Kim \[21\]                   2007   Korea          Asian       Multiple myeloma   PB        Pyrosequencing        91            69            14            857           718     125   0.28   0.127   11
  Lissowska \[22\]             2007   Poland         Caucasian   Breast             PB        PCR-RFLP              358           970           663           430           1110    753   0.43   0.558   13
  Moore \[23\]                 2007   Spain          Caucasian   Bladder            HB        Illumina              267           531           291           232           510     274   0.48   0.857   10
  Petra \[24\]                 2007   Slovenia       Caucasian   ALL                HB        PCR-RFLP              15            36            17            47            136     75    0.45   0.283   7
  Suzuki \[25\]                2007   Japan          Asian       Head and neck      HB        PCR-RFLP              108           100           29            332           315     64    0.31   0.382   9
  Suzuki \[26\]                2007   Japan          Asian       Lung               HB        Taqman                235           256           54            484           446     100   0.31   0.852   9
  Zhang \[27\]                 2007   Poland         Caucasian   Gastric            PB        Taqman                56            133           106           78            188     147   0.42   0.197   13
  Bethke \[28\]                2008   Multi-center   Caucasian   Brain              PB        Illumina              534           795           307           579           783     286   0.41   0.447   14
  Gra \[29\] ^b^               2008   Russia         Caucasian   ALL                PB        PCR-based biochip     109 (AA+AG)   31            151 (AA+AG)   95            NA      NA    7              
  Gra \[29\] ^b^               2008   Russia         Caucasian   AML                PB        PCR-based biochip     26 (AA+AG)    11            151 (AA+AG)   95            NA      NA    7              
  Gra \[30\]                   2008   Russia         Caucasian   NHL                PB        PCR-based biochip     16            40            20            33            92      52    0.45   0.492   9
  Gra \[30\]                   2008   Russia         Caucasian   CLL                PB        PCR-based biochip     20            32            31            33            92      52    0.45   0.492   9
  Ikeda \[31\]                 2008   Japan          Asian       Colorectal         HB        MassARRAY             51            47            8             132           78      12    0.23   0.914   8
  Ikeda \[31\]                 2008   Japan          Asian       Gastric            HB        MassARRAY             83            55            5             134           120     24    0.30   0.694   8
  Kim \[32\]                   2008   Korea          Asian       NHL                PB        Pyrosequencing        292           235           57            857           718     125   0.28   0.127   10
  Kwak \[33\]                  2008   Korea          Asian       Liver              PB        PCR-RFLP              40            45            9             111           78      12    0.25   0.726   7
  Lima \[34\]                  2008   Brazil         Mixed       Multiple myeloma   HB        PCR-RFLP              32            63            28            53            102     33    0.45   0.181   6
  Marchal \[35\]               2008   Spain          Caucasian   Prostate           HB        Real-time PCR         38            105           39            46            111     47    0.50   0.207   8
  Mir \[36\] ^c^               2008   India          Asian       Breast             HB        PCR-RFLP              1             27            7             0             9       24    0.14   0.364   4
  Steck \[37\]                 2008   USA            African     Colorectal         PB        Taqman                116           99            24            169           127     26    0.28   0.755   13
  Steck \[37\]                 2008   USA            Caucasian   Colorectal         PB        Taqman                53            155           99            109           256     168   0.44   0.526   13
  Suzuki \[38\]                2008   Japan          Asian       Breast             HB        Taqman                205           205           42            456           366     90    0.30   0.191   10
  Suzuki \[39\]                2008   Japan          Asian       Pancreatic         HB        Taqman                78            67            12            374           330     81    0.31   0.517   10
  Theodoratou \[40\]           2008   Scotland       Caucasian   Colorectal         PB        Illumina              200           456           339           198           482     329   0.44   0.370   12
  de Jonge \[41\]              2009   Netherlands    Caucasian   ALL                PB        Real-time PCR         59            117           66            101           245     153   0.45   0.871   7
  Kim \[42\]                   2009   Korea          Asian       ALL                PB        Pyrosequencing        58            34            15            857           718     125   0.28   0.127   9
  Kim \[42\]                   2009   Korea          Asian       AML                PB        Pyrosequencing        195           162           42            857           718     125   0.28   0.127   10
  Kim \[42\]                   2009   Korea          Asian       CML                PB        Pyrosequencing        73            68            11            857           718     125   0.28   0.127   9
  Rouissi \[43\]               2009   Tunisia        African     Bladder            PB        PCR-RFLP              59            88            38            77            85      29    0.37   0.490   5
  Burcos \[44\] ^c^            2010   Romania        Caucasian   Breast             HB        PCR-RFLP              0             37            23            3             32      25    0.32   0.072   6
  Burcos \[44\]                2010   Romania        Caucasian   Colorectal         HB        PCR-RFLP              11            64            45            7             35      18    0.41   0.108   6
  Cai \[45\]                   2010   China          Asian       Prostate           HB        PCR-RFLP              111           92            14            118           89      13    0.26   0.479   8
  Eussen \[46\]                2010   Multi-center   Caucasian   Gastric            PB        MALDI-TOF MS          58            100           81            156           286     165   0.49   0.157   12
  Sangrajrang \[47\]           2010   Thailand       Asian       Breast             HB        Taqman                295           218           46            229           210     46    0.31   0.830   11
  Tong \[48\] ^b^              2010   Korea          Asian       Cervical           HB        Multiplexed PCR       137 (AA+AG)   11            407 (AA+AG)   23            NA      NA    9              
  Wettergren \[49\]            2010   Sweden         Caucasian   Colorectal         PB        Real-time PCR         22            94            61            50            152     97    0.42   0.463   7
  Curtin \[50\]                2011   USA            Mixed       Colorectal         PB        Illumina              193           363           187           211           464     278   0.46   0.509   12
  Guimaraes \[51\]             2011   Brazil         Mixed       Colorectal         HB        PCR-RFLP              26            55            32            53            102     33    0.45   0.181   6
  Jokic \[52\]                 2011   Croatia        Caucasian   Colorectal         PB        Taqman                53            159           88            74            143     83    0.49   0.428   10
  Metayer \[53\]               2011   USA            Mixed       ALL                PB        Illumina              133           178           66            145           220     82    0.43   0.928   11
  Mostowska \[54\]             2011   Poland         Caucasian   Cervical           PB        HRM                   44            54            26            61            78      29    0.40   0.636   12
  Pardini \[55\]               2011   Czech          Caucasian   Colorectal         HB        Taqman                113           330           218           291           671     410   0.46   0.592   11
  te Winkel \[56\]             2011   Netherlands    Caucasian   ALL                PB        Real-time PCR         17            42            21            15            26      17    0.48   0.436   9
  Webb \[57\]                  2011   Australia      Mixed       Ovarian            PB        MassARRAY             584           888           405           447           730     292   0.44   0.846   12
  Weiner \[58\]                2011   Russia         Caucasian   NHL                PB        Real-time PCR         26            64            35            97            259     162   0.44   0.716   8
  Yang \[59\]                  2011   China          Asian       ALL                PB        Real-time PCR         180           154           27            198           146     23    0.26   0.568   12
  Amigou \[60\]                2012   France         Caucasian   ALL                PB        Illumina              112           187           110           95            226     120   0.47   0.553   13
  Galbiatti \[61\] ^a^         2012   Brazil         Mixed       Head and neck      PB        Real-time PCR         69            196 (AG+GG)   149           317 (AG+GG)   NA      NA    10             
  Lajin \[62\]                 2012   Syria          Caucasian   Breast             PB        ARMS-PCR              40            59            20            43            58      25    0.43   0.499   4
  Pawlik \[63\]                2012   Poland         Caucasian   Ovarian            PB        HRM                   47            68            19            63            68      29    0.39   0.165   12
  Weiner \[64\]                2012   Russia         Caucasian   Breast             PB        Real-time PCR         162           387           285           158           394     216   0.46   0.376   12
  Yoo \[65\]                   2012   Korea          Asian       Gastric            HB        MassARRAY             655           513           81            212           135     22    0.24   0.934   7
  Yoshimitsu \[66\]            2012   Japan          Asian       Colorectal         HB        PCR-RFLP              281           198           39            490           454     107   0.32   0.903   10
  Yuan \[67\]                  2012   China          Asian       Gastric            HB        MassARRAY             27            112           140           17            114     165   0.25   0.642   7
  Chen \[68\]                  2013   China          Asian       Cervical           HB        PCR-RFLP              50            46            11            54            44      9     0.29   0.993   7
  Jackson \[69\] ^a^           2013   Jamaica        African     Prostate           HB        Taqman                111           84 (AG+GG)    120           83 (AG+GG)    NA      NA    7              
  Liu \[70\]                   2013   USA            Mixed       Colorectal         PB        Illumina              264           717           439           356           869     550   0.45   0.704   12
  Morita \[71\]                2013   Japan          Asian       Colorectal         PB        PCR-RFLP              342           278           65            361           343     74    0.32   0.565   11
  Tomita \[72\]                2013   Brazil         Mixed       Cervical           HB        Allele-specific PCR   70            90            40            38            43      19    0.41   0.281   8
  Zhang \[73\]                 2013   China          Asian       Brain              PB        PCR-RFLP              209           269           122           225           282     93    0.39   0.765   12
  Chang \[74\]                 2014   China          Asian       Gastric            PB        Taqman                119           63            9             204           149     25    0.26   0.752   12
  Chang \[74\]                 2014   China          Asian       Liver              PB        Taqman                114           64            13            204           149     25    0.26   0.752   11
  Chang \[74\]                 2014   China          Asian       Esophagus          PB        Taqman                117           74            10            204           149     25    0.26   0.752   12
  Xu \[75\]                    2014   China          Asian       Liver              HB        SNaPshot              103           86            16            112           73      15    0.26   0.520   6
  Gong \[76\]                  2015   USA            Caucasian   Breast             PB        Illumina              158           318           140           165           321     138   0.48   0.442   14
  Greenop \[77\]               2015   Australia      Mixed       Brain              PB        MassARRAY             80            148           90            102           264     175   0.43   0.890   11
  Suthandiram \[78\]           2015   Multi-center   Asian       NHL                HB        MassARRAY             178           153           41            353           306     63    0.30   0.774   10
  Kim \[79\]                   2016   Korea          Asian       Gastric            HB        Affymetrix Array      136           111           23            295           211     35    0.26   0.739   10
  Nakao \[80\]                 2016   Japan          Asian       Pancreatic         HB        Dynamic Array         167           157           36            206           158     36    0.29   0.473   11
  Peres \[81\]                 2016   Brazil         Mixed       Liver              HB        Real-time PCR         12            50            9             105           179     72    0.45   0.787   8
  Tao \[82\]                   2016   China          Asian       Breast             HB        MassARRAY             175           85            38            162           115     21    0.26   0.924   9

MAF, minor allele frequency; HB: hospital based; PB: population based; NA, not applicable; PCR-RFLP: polymorphism chain reaction restriction fragment length polymorphism; MALDI-TOF MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; HRM: high resolution melt; ARMS-PCR: amplification refractory mutation system-PCR; ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin\'s lymphoma; AML: acute myelogenous leukemia; CML: chronic myelogenous leukemia; CLL: chronic lymphocytic leukemia.

^a^ Chen [@B17], Galbiatti [@B61] and Jackson [@B69] were only calculated for the dominant model.

^b^ Gra [@B29] and Tong [@B48] were only calculated for the recessive model.

^c^ Mir [@B36] and Burcos [@B44] (breast cancer) were only calculated for the recessive model and allele comparison, and the number of AA genotype was zero.

###### 

Meta-analysis of the association between *MTRR* A66G polymorphism and cancer risk.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables           No. of studies   Sample size\      Homozygous             Heterozygous   Recessive          Dominant   Allele comparison                                                                        
                                       (case/controls)                                                                                                                                                                
  ------------------- ---------------- ----------------- ---------------------- -------------- ------------------ ---------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  All ^a^             85               32,272/37,427     **1.08 (1.02-1.15)**   0.009          1.01 (0.97-1.06)   0.007      **1.06 (1.00-1.12)**   \<0.001   1.04 (0.99-1.08)       0.001     **1.03 (1.00-1.06)**   \<0.001

  Cancer type                                                                                                                                                                                                         

  Colorectal          20               8,057/10,465      1.09 (0.96-1.25)       0.031          1.05 (0.95-1.16)   0.030      1.04 (0.97-1.11)       0.462     1.07 (0.97-1.19)       0.006     1.05 (0.98-1.12)       0.007

  Breast              10               6,048/5,872       1.08 (0.96-1.21)       0.488          0.99 (0.89-1.11)   0.131      0.99 (0.81-1.22)       0.001     1.02 (0.94-1.11)       0.362     1.01 (0.92-1.11)       0.018

  ALL                 9                1,893/3,770       0.90 (0.72-1.13)       0.228          0.88 (0.76-1.03)   0.367      0.89 (0.70-1.14)       0.013     0.89 (0.78-1.02)       0.472     0.93 (0.85-1.02)       0.547

  Gastric             8                2,756/2,504       0.96 (0.72-1.29)       0.054          0.95 (0.80-1.12)   0.159      1.02 (0.82-1.27)       0.109     0.94 (0.78-1.14)       0.041     0.97 (0.84-1.12)       0.010

  NHL                 5                1,357/1,674       1.00 (0.74-1.35)       0.126          0.97 (0.84-1.11)   0.998      0.99 (0.74-1.33)       0.053     0.99 (0.87-1.13)       0.911     0.99 (0.89-1.11)       0.295

  Cervical            4                579/805           1.22 (0.80-1.86)       0.968          1.07 (0.78-1.46)   0.882      1.77 (0.98-3.20)       0.029     1.11 (0.83-1.48)       0.945     1.10 (0.90-1.36)       0.982

  Liver               4                561/757           1.19 (0.79-1.78)       0.600          1.33 (0.84-2.10)   0.011      0.97 (0.65-1.45)       0.335     1.29 (0.86-1.94)       0.022     1.11 (0.89-1.38)       0.151

  Brain               3                2,554/2,789       1.05 (0.72-1.52)       0.009          0.98 (0.79-1.21)   0.091      1.08 (0.84-1.40)       0.054     0.99 (0.77-1.27)       0.029     1.02 (0.85-1.22)       0.014

  Head and neck       3                1,223/1,700       **1.49 (1.17-1.89)**   0.768          1.24 (0.79-1.94)   0.025      1.15 (0.96-1.38)       0.346     **1.30 (1.03-1.64)**   0.143     **1.17 (1.04-1.31)**   0.560

  Prostate            3                594/627           1.05 (0.65-1.71)       0.798          1.12 (0.82-1.52)   0.899      0.96 (0.64-1.44)       0.689     1.10 (0.87-1.40)       0.999     1.04 (0.84-1.27)       0.718

  Other cancers       16               6,650/6,464       1.14 (1.01-1.28)       0.282          1.01 (0.94-1.10)   0.335      1.10 (1.01-1.20)       0.533     1.06 (0.97-1.15)       0.211     1.06 (1.00-1.11)       0.340

  Ethnicity                                                                                                                                                                                                           

  Asian               37               11,829/13,248     1.11 (0.99-1.24)       0.080          0.98 (0.92-1.05)   0.063      1.09 (0.97-1.22)       0.006     1.01 (0.95-1.08)       0.019     1.02 (0.97-1.08)       0.001

  Caucasian           32               13,351/16,506     **1.09 (1.00-1.19)**   0.077          1.08 (0.99-1.16)   0.078      1.03 (0.96-1.09)       0.144     **1.08 (1.00-1.17)**   0.045     **1.05 (1.01-1.09)**   0.193

  African             3                619/716           **1.52 (1.00-2.32)**   0.577          1.21 (0.92-1.60)   0.553      1.36 (0.92-2.02)       0.751     1.21 (0.97-1.51)       0.624     **1.23 (1.01-1.49)**   0.474

  Mixed               13               6,473/6,957       1.01 (0.88-1.15)       0.084          0.96 (0.86-1.06)   0.184      1.12 (0.96-1.32)       \<0.001   1.00 (0.90-1.11)       0.075     1.01 (0.94-1.07)       0.088

  Source of control                                                                                                                                                                                                   

  PB                  52               21,300/24,134     1.06 (0.99-1.14)       0.087          0.99 (0.94-1.04)   0.304      1.05 (0.99-1.11)       0.037     1.01 (0.97-1.06)       0.135     1.02 (0.99-1.06)       0.075

  HB                  33               10,972/13,293     1.12 (0.99-1.26)       0.019          1.06 (0.97-1.16)   0.002      1.07 (0.94-1.21)       \<0.001   1.08 (0.99-1.18)       0.001     1.04 (0.98-1.11)       \<0.001

  Score                                                                                                                                                                                                               

  Low                 37               6,610/9,768       1.13 (0.99-1.29)       0.265          1.05 (0.96-1.16)   0.144      1.06 (0.90-1.24)       0.000     1.08 (0.99-1.17)       0.299     1.05 (0.98-1.12)       0.042

  High                48               25,662/27,659     **1.07 (1.00-1.15)**   0.005          1.00 (0.95-1.05)   0.010      **1.06 (1.01-1.11)**   0.262     1.02 (0.97-1.08)       \<0.001   1.02 (0.99-1.06)       0.001
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Het, heterogeneity; ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin\'s lymphoma; PB: population based; HB: hospital based.

^a^ The number of controls was only calculated once if the same controls were used.

###### 

False-positive report probability values for associations between cancer risk and genotypes of *MTRR* A66G polymorphism.

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Genotype                           Crude OR\          *P*-value ^a^   Statistical\   Prior probability                                   
                                     (95% CI)                           Power ^b^                                                          
  ---------------------------------- ------------------ --------------- -------------- ------------------- ----------- ----------- ------- -------
  All patients                                                                                                                             

  Homozygous                         1.08 (1.02-1.15)   0.016           1.000          **0.047**           **0.128**   0.618       0.942   0.994

  Recessive                          1.06 (1.00-1.12)   0.038           1.000          **0.102**           0.255       0.790       0.974   0.997

  Allele comparison                  1.03 (1.00-1.06)   0.044           1.000          **0.116**           0.282       0.812       0.978   0.998

  Cancer type-head and neck cancer                                                                                                         

  Homozygous                         1.49 (1.17-1.89)   0.001           0.522          **0.006**           **0.017**   **0.161**   0.660   0.951

  Dominant                           1.30 (1.03-1.64)   0.027           0.886          **0.083**           0.214       0.750       0.968   0.997

  Allele comparison                  1.17 (1.04-1.31)   0.006           1.000          **0.019**           **0.055**   0.391       0.886   0.985

  Ethnicity-Caucasian                                                                                                                      

  Homozygous                         1.09 (1.00-1.19)   0.054           1.000          **0.140**           0.328       0.843       0.982   0.998

  Dominant                           1.08 (1.00-1.17)   0.059           1.000          **0.151**           0.349       0.885       0.983   0.998

  Allele comparison                  1.05 (1.01-1.09)   0.010           1.000          **0.031**           **0.087**   0.511       0.913   0.991

  Ethnicity-African                                                                                                                        

  Homozygous                         1.52 (1.00-2.32)   0.052           0.476          0.248               0.497       0.916       0.991   0.999

  Allele comparison                  1.23 (1.01-1.49)   0.034           0.979          **0.095**           0.240       0.777       0.972   0.997

  Score-high                                                                                                                               

  Homozygous                         1.07 (1.00-1.15)   0.066           1.000          **0.165**           0.372       0.867       0.985   0.998

  Recessive                          1.06 (1.01-1.11)   0.013           1.000          **0.038**           **0.106**   0.567       0.930   0.992
  ------------------------------------------------------------------------------------------------------------------------------------------------

^a^Chi-square test was used to calculate the genotype frequency distributions.

^b^Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.

[^1]: ^\*^ These authors contributed equally to this work.
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